膀胱腺癌、尿路上皮癌与鳞状细胞癌的免疫肿瘤生物标志物综合评估
基于Foundation Medicine数据库,对143例纯膀胱腺癌(ACB)、2142例纯尿路上皮癌(UC)和83例纯鳞状细胞癌(SCC)进行综合基因组谱分析(CGP)和免疫组化。UC和SCC的中位肿瘤突变负荷(TMB)显著高于ACB(p<0.001),PD-L1表达频率在UC和SCC中均为30%,高于ACB的18%;SCC中CD274扩增频率最高(5% vs UC 1%)。纯SCC不应被排除在免疫治疗试验之外。
要点
- UC和SCC的中位TMB显著高于ACB(p<0.001)。
- PD-L1在肿瘤细胞和浸润淋巴细胞中的表达频率UC和SCC均为30%,ACB为18%。
- SCC中CD274扩增频率为5%,高于UC的1%,ACB中未见。
核心结论
- 膀胱癌三种主要亚型间免疫肿瘤生物标志物存在显著差异。
- UC和SCC的PD-L1表达频率及TMB高于ACB,SCC的CD274扩增频率最高。
- 具有纯SCC特征的患者不应被排除在免疫治疗试验之外。
研究设计与样本
- 比较性综合基因组谱分析(CGP)研究,数据来自Foundation Medicine数据库。
- 纳入143例纯ACB、2142例纯UC和83例纯SCC,所有患者均为膀胱癌原发诊断后进展为晚期疾病。
- 采用基于杂交捕获的CGP assay和免疫组化(IHC)进行检测。
主要发现
- 纯ACB患者较纯UC和纯SCC患者更年轻且女性比例更高。
- UC和SCC的中位TMB显著高于ACB(p<0.001)。
- CD274(PD-L1)扩增在SCC中更常见(5% vs UC 1%),ACB中未见。
- MSI高状态在所有肿瘤类型中均罕见(0-1%)。
- PD-L1在肿瘤细胞和肿瘤浸润淋巴细胞中的表达频率UC和SCC均为30%,ACB为18%。
关键数值与推荐
- TMB在1.1 Mbp测序DNA上确定,MSI在114个位点上确定。
- PD-L1表达通过IHC(Ventana SP-142 assay)确定,>1%肿瘤细胞或肿瘤浸润淋巴细胞评分阳性。
临床怎么用
- 对于纯SCC膀胱癌患者,应考虑纳入免疫治疗试验。
- 纯ACB可能具有不同的治疗机会,如针对特定基因组改变的靶向治疗。
局限性
- 研究为回顾性性质。
- 缺乏临床数据注释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with rare histologies of bladder cancer, including adenocarcinoma of the bladder (ACB) and squamous-cell carcinoma (SCC), there are limited standard therapy options, defining an unmet medical need. OBJECTIVE: In this comparative comprehensive genomic profiling (CGP) study, genomic alterations (GAs), and immuno-oncology (IO) biomarkers have been analyzed. DESIGN, SETTING, AND PARTICIPANTS: Within the Foundation Medicine database, 143 cases with centrally reviewed pure ACB, 2142 with pure urothelial carcinoma (UC), and 83 with pure SCC were subjected to CGP. All patients developed advanced disease following a primary diagnosis of bladder cancer. INTERVENTION: CGP using a hybrid capture-based assay and immunohistochemistry (IHC). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Tumor mutational burden (TMB) was determined on 1.1 Mbp of sequenced DNA, and microsatellite instability (MSI) was determined on 114 loci. Programmed cell-death ligand-1 (PD-L1) expression was determined by IHC (Ventana SP-142 assay), with >1% tumor cells (TCs) or tumor-infiltrating lymphocytes (TILs) scoring positive. RESULTS AND LIMITATIONS: Pure ACB patients were younger and more often female than pure UC and pure SCC patients. UC and SCC had a significantly higher median TMB than ACB (p < 0.001). Rare CD274 (PD-L1) amplification cases were more frequently seen in SCC than in UC (5% vs 1%), and were not seen in ACB. MSI high status was very uncommon in all tumor types (0-1%). The frequencies of PD-L1 expression in both TCs and TILs was higher in UC and SCC (both 30%) than in ACB (18%). The results are limited by their retrospective nature and lack of clinical data annotation. CONCLUSIONS: Deep sequencing revealed significant differences in IO biomarkers among the three major subtypes of bladder carcinomas. UC and SCC revealed higher frequencies of PD-L1 expression and higher TMB than ACB, and SCC has the highest frequency of CD274 amplification. The presence of pure SCC features should not disqualify patients for inclusion in IO trials. PATIENT SUMMARY: Tumor samples from patients diagnosed with advanced pure adenocarcinoma of the bladder (ACB) or pure squamous-cell carcinoma (SCC) have been analyzed in terms of frequency of putative immunotherapy biomarkers. The results indicated that pure SCC of the bladder was characterized by genomic features that portend similar response possibilities to immunotherapy compared with the classical pure urothelial carcinoma. Conversely, for pure ACB there might be different therapeutic opportunities, such as targeted therapies against peculiar genomic alterations in selected patients.
引用
- Necchi A, Madison R, Raggi D, et al. Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder. Eur Urol. 2020. PMID: 31959546. doi:10.1016/j.eururo.2020.01.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。